# KLOW peptide references: the component research and recent literature

> KLOW peptide references — the full cited source list for the four components (KPV, GHK-Cu, BPC-157, TB-500) with DOIs and PubMed links.

Every cited study behind this site, component by component, with DOIs and PubMed links you can verify.

## How to read this list

Every numbered citation across the site resolves here. The list is entirely component-level — studies of KPV, GHK-Cu, BPC-157 and TB-500 (or its parent protein thymosin beta-4) studied alone — plus the recent reviews and the regulatory references. There is no entry for a KLOW blend trial, because none has been published. Where a study used full-length thymosin beta-4 rather than the TB-500 fragment, that distinction is noted in the citation text so the two are never read as one.

## References

[1] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Used here for the blend-is-untested and regulatory-oversight statements.) https://pubmed.ncbi.nlm.nih.gov/41966639/
[2] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[4] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[6] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. (Full-length thymosin beta-4, not the TB-500 fragment.) https://pubmed.ncbi.nlm.nih.gov/10469335/
[7] Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Lists TB-500/thymosin beta-4 and BPC-157; used here for FDA non-approval, WADA status and regulatory-oversight context.) https://pubmed.ncbi.nlm.nih.gov/41966639/
[9] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. (Establishes TB-500's parent protein, thymosin beta-4, as the named peptide hormone/growth factor on the WADA Prohibited List S2 category.) https://pubmed.ncbi.nlm.nih.gov/20536472/
[10] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[11] Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011;60(1):79-86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[12] Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. https://pubmed.ncbi.nlm.nih.gov/12750433/
[13] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. https://pubmed.ncbi.nlm.nih.gov/40131143/
[14] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. (Phase 1; full-length thymosin beta-4, not the TB-500 fragment.) https://pubmed.ncbi.nlm.nih.gov/20536472/
[15] Dymek M, Olechowska K, Hac-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. https://pmc.ncbi.nlm.nih.gov/articles/PMC10610410/
[16] Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. (Retrospective case series, n=16.) https://pubmed.ncbi.nlm.nih.gov/34324435/
[17] Morris DC, et al. A dose-response study of thymosin beta4 for the treatment of acute stroke. J Neurol Sci. 2014. (Full-length thymosin beta-4; non-monotonic dose response.) https://pubmed.ncbi.nlm.nih.gov/25060418/
[18] Author group. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/

---

A calm, plain-English reading of the four-peptide KLOW record — each ingredient's studies surfaced gently and the untested blend named as the honest gap it is, with no clinic behind the page and nothing here dosed or sold.